266 results on '"Uike, N."'
Search Results
2. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma
3. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients
4. Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab
5. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project
6. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms
7. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma
8. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan
9. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials
10. A PROGNOSTIC INDEX FOR ACUTE AND LYMPHOMA TYPE ADULT T-CELL LEUKEMIA/LYMPHOMA
11. Prevalence of hepatitis C virus infection in cases of B-cell lymphoma in Japan
12. Genetic changes in atypical hyperplasia and lymphoma with angioimmunoblastic lymphadenopathy and dysproteinaemia in the same patients
13. Epstein–Barr virus-associated T cell lymphoproliferative disorder following autologous blood stem cell transplantation for relapsed Hodgkin's disease
14. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505
15. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
16. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan
17. PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA
18. Randomized phase II study of biweekly CHOP anddose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma: Japan Clinical Oncology Group Study 9505
19. Immunoglobulin class switch from IgA1 to IgG2 and simultaneous association with Bence Jones proteinuria in the escape phase in a myeloma patient treated with interferon alpha
20. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study
21. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project
22. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma
23. CD30-Positive anaplastic large cell lymphoma in a human T-cell lymphotropic virus-I endemic area
24. 533 Extended treatment-free interval with excellent life more than two years after autologous dendritic cell vaccine therapy targeting HTLV-1 Tax for previously treated adult T-cell leukemia/lymphoma: The follow-up kinetics of cytotoxic T lymphocytes and HTLV-1 viral load
25. 3228 Cure of adult T-cell leukemia/lymphoma by allogeneic stem cell transplantation with reduced conditioning intensity - End results for the patients who received prospective trials
26. 3228 Cure of adult T-cell leukemia/lymphoma by allogeneic stem cell transplantation with reduced conditioning intensity - End results for the patients who received prospective trials
27. Excellent Quality of Lives for Previously Treated Adult T-Cell Leukemia/Lymphoma Patients After Autologous Dendritic Cell Vaccine Therapy Targeting Htlv-1 Tax Antigens
28. Bendamustine with Rituximab for Relapsed or Refractory Low-Grade B-Cell Lymphoma
29. A Multicenter Phase II Study of Bendamustine with Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
30. Angiocentric immunoproliferative lesions of the skin show lobular panniculitis and are mainly disorders of large granular lymphocytes
31. [A case of primary non-Hodgkin lymphoma of the adrenal gland presenting with Addison's disease]
32. [i(17q) appearing in acute phase in Ph1-negative, BCR-negative CML]
33. Late phase II study of amrubicin in previously untreated patients with non-Hodgkin’s lymphoma (NHL)
34. 983P - Excellent Quality of Lives for Previously Treated Adult T-Cell Leukemia/Lymphoma Patients After Autologous Dendritic Cell Vaccine Therapy Targeting Htlv-1 Tax Antigens
35. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies
36. Angiocentric immunoproliferative lesions of the skin show lobular panniculitis and are mainly disorders of large granular lymphocytes
37. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies
38. CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics
39. Heterogeneity of Epstein-Barr virus infection in angioimmunoblastic lymphadenopathy type T-cell lymphoma
40. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma.
41. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.
42. Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study.
43. Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial.
44. Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells.
45. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: Comparative study.
46. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.
47. Angiodestruction and tissue necrosis of skin-involving CD56+ NK/T-cell lymphoma are influenced by expression of cell adhesion molecules and cytotoxic granule and apoptosis-related proteins.
48. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
49. Establishment of a human myeloma cell line with growth-promoting activity for bone marrow-derived fibroblastoid colony-forming cells
50. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.